

Discovery of therapeutic small molecules targeting alpha-synuclein aggregation



Elpida Tsika, PhD | AD/PDTM | 31 March 2023

www.acimmune.com

Disclaimer

This presentation contains statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions "Item 3. Key Information – Risk Factors" and "Item 5. Operating and Financial Review and Prospects" in AC Immune's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are date they are fully in their entirety by this cautionary statement.

This presentation is strictly confidential, is being distributed to a limited range of invited persons solely for their own information, may not be distributed to the press or any other person, and may not be reproduced or published, in whole or in part, in any form.

SupraAntigen[®] is a registered trademark of AC Immune SA in the following territories: AU, CH, EU, GB, JP, RU, SG and USA. Morphomer[®] is a registered trademark of AC Immune SA in CH, CN, GB, JP, KR, NO and RU.

Conflict of interest disclosure

Employee of AC Immune SA entitled to stock options.



Parkinson's disease

Pathological deposition of alpha-synuclein



Most common neurodegenerative movement disorder Affects ~1% of the population over 65 years



Etiology 5-10% genetic, 90-95% idiopathic, unknown cause



Cardinal motor symptoms Tremor, rigidity, bradykinesia




Common non-motor symptoms Sleep disorder, depression, cognitive impairment




Pathological hallmarks

Neuron loss, alpha-synuclein aggregates – Lewy bodies

Main component of Lewy bodies: Alpha-synuclein



Progression of pathology




Braak et al. 2003





Proprietary Morphomer[®] platform

Targeting alpha-synuclein aggregation with small molecules



- Robust library of conformation-specific, non-peptidic small molecules with desirable CNS¹ properties constructed and continually refined and expanded over many years
- Comprehensive screening, rational design and early validation processes rapidly generate highly specific hit compounds
- Clinically validated with two diagnostic and one therapeutic candidate in clinical development


(1) CNS: Central Nervous System






Discovering inhibitors of alpha-synuclein (a-syn) aggregation

Morphomers® target intracellular pathological aggregates and intraneuronal spreading



Inhibition of a-syn aggregation in vitro

Thioflavin T monitored β -sheet content and conversion to insoluble aggregates



Morphomer® compounds:


- inhibit formation of β-sheet-rich structures, monitored by Thioflavin T
- prevent the conversion of a-syn into fibrillar, insoluble conformations, shown by sedimentation analysis

AD/PD[™] | 31 March 2023



Inhibition of a-syn aggregation in vitro

Fluorescence polarization-monitored effects on size and conversion to insoluble aggregates



Morphomer® compounds:

- inhibit a-syn aggregation into high molecular weight species, monitored by fluorescence polarization
- prevent the conversion of a-syn into fibrillar, insoluble conformations, shown by sedimentation analysis

(1) Fluorescence polarization




AD/PD™| 31 March 2023

© 2023 AC Immune | Not to be used or reproduced without permission

Aggregate binding specificity

Recombinant a-syn monomer vs fibrils



Direct immobilization of a-syn monomer or fibrils to the SPR sensor chip

Morphomer® compound Z, shown as example, demonstrates specific binding to aggregated a-syn:


- Radiobinding assay on a-syn fibrils vs a-syn monomer
- Label-free binding assessment by SPR¹

(1) Surface plasmon resonance



Inhibition of a-syn aggregation in cells

PFF¹-seeded HEK² cells overexpressing human a-syn with eGFP³ reporter



• PFF addition to HEK-a-syn-eGFP cells leads to accumulation of detergent-insoluble, intracellular aggregates


• Treatment of cells with Morphomer[®] compounds results in reduction of intracellular aggregates

(1) Preformed fibrils; (2) Human embryonic kidney; (3) enhanced green fluorescent protein



Inhibition of pathological a-syn aggregation in neurons

MSA¹-seeded rat cortical neurons




Morphomer[®] treatment reduces burden of intracellular a-syn aggregates with IC₅₀ in nanomolar range

(1) Multiple system atrophy; (2) Phospho-Serine 129



Target engagement on PD¹-derived aggregates

High-resolution autoradiography, radiobinding assessment



Compound Z concentration [nM]

Binding to PD brain-enriched a-syn aggregates - radiobinding

- Compound Z partially displaces [3H]ACI-12589² binding to a-syn aggregates on PD amygdala tissue
- Ki in sub-μM range for the displacement of [3H]ACI-12589 binding to a-syn aggregates extracted from PD brain


(1) Parkinson's disease; (2) a-syn PET tracer candidate



Pharmacokinetic studies

Oral administration (20mg/kg) in mice

Compound Z administered p.o.¹ once or repeatedly over 10 days; total concentration measured over 72 hours post-dose



- Accumulation observed in plasma, brain and CSF²
- Compound Z highly exposed in the CNS³


(1) Per os; (2) Cerebrospinal fluid; (3) Central Nervous System



Ref: Tsika et al. MDS 2022

Compound Z evaluation in proof-of-concept in vivo study


Via food administration in the a-syn hPFF¹ model on the M83 line





Started dosing 48h following surgeries







Group	Inoculum	Treatment
А	PBS	Vehicle (normal chow)
В	hPFF	Vehicle (normal chow)
С	hPFF	100mg/kg Compound Z
D	hPFF	60mg/kg Compound Z

- 3 months post-hPFF injection pathological a-syn detected in brain regions anatomically connected to the injection site (AON⁴): cortical areas, hippocampus and brainstem, in both ipsilateral and contralateral hemispheres.
- · Neuronal loss, mainly in ipsilateral hemisphere, can confound interpretation of treatment effects so analysis is focused on regions with no cell death


Readout: pS129 a-syn aggregates in brain regions interconnected to injection site

(1) hPFF: human preformed fibrils; (2) NeuN: neuronal marker; (3) IHC: immunohistochemistry; (4) AON: anterior olfactory nucleus




Decrease of pS129 a-syn in various brain areas

Compound Z evaluation in proof-of-concept in vivo study



pS129 a-syn levels



2-way ANOVA, Group A excluded. Transformation log(1+x)

Morphomer® treatment significantly reduces pathological a-syn in the brain

(1) NeuN: neuronal marker; (2) EntCx: entorhinal cortex; (3) HC: hippocampus



Ref: AC Immune unpublished data

Summary

Discovered novel a-syn aggregation inhibitors using our Morphomer® platform which:

- inhibit formation of β-sheet-rich, insoluble aggregates
- reduce burden of intracellular aggregates
- show target engagement to pathological species

First orally available and CNS penetrant Morphomer® which significantly reduces pathology in an animal model of Parkinson's disease

Several chemical series identified; Medicinal chemistry optimization ongoing to identify lead candidate





Acknowledgements



Andrea Pfeifer	Nac
Marie Kosco-Vilbois	Nico
Sonia Poli	Cor
Heiko Kroth	Leo
Nicolas Fournier	Lor
Clarisse Schumer	Sylv
Thomas Jaquier	Seb
Alexis Fenyi	Joh
Ruth Luthi-Carter	Irina

Nadine Ait-Bouziad Nicolas Dreyfus Coralie Vallet Leonida Maliqi Lorène Aeschbach Sylvain Pautet Sebastien Menant Johannes Brune Irina Borovko



Brain tissue samples:

Netherlands Brain Bank

The University of Miami's Brain Endowment Bank

All the donors and their families for their indispensable contributions to research!

HEK-a-syn-eGFP cell line provided by Prof. Outeiro University Medical Center Goettingen, Germany

The work was supported by grant MJFF-021171 from the Michael J. Fox Foundation for Parkinson's Research





AC Immune: Pioneering science and precision medicine

Shifting the treatment paradigm for neurodegenerative disease towards precision medicine and disease prevention







Presenter:

https://www.acimmune.com/

www.linkedin.com/company/ac-immune

elpida.tsika@acimmune.com

